News
Novo Nordisk shares fall further as new CEO faces US challenges
COPENHAGEN, DENMARK (Reuters) -Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker's value.
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...
European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...
1mon
The story of how Novo Nordisk will lose billions because it didn’t pay a couple of hundred dollars
Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.
July 29 - Novo Nordisk (NOVO?B) shares plunged about 20% Tuesday after the Danish drugmaker warned of weaker-than?expected ...
storage.googleapis.com on MSN22h
Novo Nordisk (NVO) Just Lost $100B and Blamed HIMS
Novo Nordisk ($NVO) lost nearly $100 billion in market cap in one session and pointed fingers at Hims & Hers Health ($HIMS) as the reason. Shay calls out the absurdity of a $300B company blaming a ...
Zacks Investment Research on MSN5d
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback